Eriko Tokunaga

TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.

TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: The postoperative prognosis for each type of recurrence of gastric cancer is investigated in a variety of forms and in different organs after ‘curative resection’.

TL;DR: This review describes Akt signaling pathway components and its cellular functions as well as the alterations in human cancers and the therapeutic approaches for targeting the Akt pathway in cancer.